Variant · Amplification
PIK3CA Amplification
CI-VAR-00000202Explore in graph →CIViC 212
Curated evidence
Evidence by cancer (8 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 22292935
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Gastric Adenocarcinoma1 | ||||||||
| PIK3CA Amplification | (prognostic) | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID504In patients with gastric cancer, those with amplification of PIK3CA had shorter overall survival than those without amplification. PMID 22292935 · Shi et al., 2012 · Open in CIViC | civic |
| Gastric Carcinoma1 | ||||||||
| PIK3CA Amplification | Alpelisib | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1403474 cancer cell lines from the cancer cell line encyclopedia were assessed for response to the PI3Kalpha inhibitor BYL719 (Alpelisib). PIK3CA amplification was significanly associated with BYL719 resp… (full text at CIViC) PMID 24608574 · Fritsch et al., 2014 · Open in CIViC | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available